New technologies and personalised care are improving outcomes in 2025
doi: 10.1016/j.aquaculture.2020.735428 347 XiongF.ChenS.JakovliI.LiW.LiM.ZouH.et al
the information below is extrapolated from authorised GLP-1 and GLP-1/GIP receptor agonists (such as semaglutide and tirzepatide) and should be interpreted accordingly
Outcomes In our analysis of nine studies comparing GLP-1RAs to placebo for WL following bariatric surgery, we found no significant differences between the two groups (SMD = 0.56, 95% CI -0.19 to 1.30) (Fig
Anyone considering the use of retatrutide, sermorelin, or a combination of the two should seek advice from a qualified UK prescriber before proceeding
This article examines the evidence on tirzepatide side effects and cancer risk, reviews FDA safety monitoring, and provides guidance on when to seek medical attention